Risk of Fracture with Thiazolidinediones: Disease or Drugs?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The use of thiazolidinediones (TZDs) has been associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) has been linked with fracture. We evaluated to what extent the association between TZD use and fracture risk is related to the drug or to the underlying disease. We conducted a population-based cohort study using the Danish National Health Registers (1996-2007), which link pharmacy data to the national hospital registry. Oral antidiabetic users (n = 180,049) were matched 1:3 by year of birth and sex to nonusers. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture. Time-dependent adjustments were made for age, comorbidity, and drug use. We created a proxy indicator for the severity of disease. The first stage was defined as current use of either a biguanide or a sulfonyluerum, the second stage as current use of a biguanide and a sulfonyluerum at the same time, the third stage as patients using TZDs, and the fourth stage as patients using insulin. The risk of osteoporotic fracture was increased 1.3-fold for stages 3 and 4 compared with controls. Risk with current TZD use (stage 3 HR = 1.27, 95 % CI 1.06-1.52) and risk with current use of insulin (stage 4 HR = 1.25, 95 % CI 1.20-1.31) were similar. In the first (HR = 1.15, 95 % CI 1.13-1.18) and second (HR = 1.00, 95 % CI 0.96-1.04) stages risks were lower. Risk of osteoporotic fracture was similar for TZD users and insulin users. When studying fracture risk with TZDs, the underlying T2DM should be taken into account.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FRAX™ and the assessment of fracture probability in men and women from the UK
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0543-5 · Cited by 2,467
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Nguyen, N. T., Nguyen, X.-M. T., Lane, J., & Wang, P. (2011) · Obesity Surgery · doi:10.1007/s11695-010-0335-4 · Cited by 385 · cited 4×
“However, we did adjust our analyzes for the use of statins, which is probably correlated with high BMI.”
BackgroundInfluential
Cited by
Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2924 · Cited by 271
Driessen, J. H. M., Henry, R. M. A., van Onzenoort, H. A. W., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G. M., & de Vries, F. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9993-5 · Cited by 79
“For instance, thiazolidinediones [4–6] have shown to increase & Frank de Vries f.”
Self-citationBone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4096 · Cited by 47
Shen, W.-R., Kimura, K., Ishida, M., Sugisawa, H., Kishikawa, A., Shima, K., Ogawa, S., Qi, J., & Kitaura, H. (2018) · Journal of Immunology Research · doi:10.1155/2018/5783639 · Cited by 45
DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo
Ishida, M., Shen, W.-R., Kimura, K., Kishikawa, A., Shima, K., Ogawa, S., Qi, J., Ohori, F., Noguchi, T., Marahleh, A., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.052 · Cited by 36
Metadata
- Authors
- Bazelier, M. T., Vestergaard, P., Gallagher, A. M., van Staa, T.-P., Cooper, C., Leufkens, H. G. M., & de Vries, F.
- Venue
- Calcified Tissue International
- Published
- 2012-04-10
- Volume
- 90
- Issue
- 6
- Pages
- 450-457
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W2045993589
- Cited by
- 28
- References
- 3
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of Fracture with Thiazolidinediones: Disease or Drugs? https://app.cochat.ai/papers/10.1007/s00223-012-9591-8
- The paper
- Bazelier, M. T., Vestergaard, P., Gallagher, A. M., van Staa, T.-P., Cooper, C., Leufkens, H. G. M., & de Vries, F. (2012). Risk of Fracture with Thiazolidinediones: Disease or Drugs? Calcified Tissue International. https://doi.org/10.1007/s00223-012-9591-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.